Metformin-induced encephalopathy in a peritoneal dialysis patient: the critical role of hemodialysis in reversing lentiform fork sign: a case report
Abstract
BACKGROUND: Metformin remains a first-line therapy for type 2 diabetes mellitus. However, its use in patients with end-stage renal disease (ESRD), particularly those on dialysis, carries risks such as lactic acidosis and encephalopathy. Metformin-induced extrapyramidal syndrome accompanied by encephalopathy is rare. CASE PRESENTATION: We report a 60-year-old man on peritoneal dialysis (PD), for glomerulonephritis who developed metformin-induced encephalopathy shortly after initiating the drug for new-onset diabetes. In addition to extrapyramidal symptoms, such as tremor in the right upper limb, the patient exhibited significant higher cortical dysfunction—manifested as markedly slowed responsiveness, lethargy, apparent apathy, psychomotor slowing, cognitive impairment, drooling, and failure to recognize familiar faces. These features reflect a severe neuropsychiatric phenotype that has rarely been emphasized in previous reports of metformin-associated encephalopathy. Brain magnetic resonance imaging showed symmetric basal ganglia hyperintensities with the "lentiform fork sign." Neurological symptoms persisted despite metformin discontinuation and only improved after transitioning to hemodialysis. A mild resting tremor remained at 24-month follow-up. DISCUSSION: This case illustrates metformin-induced extrapyramidal syndrome with encephalopathy in a patient with ESRD on dialysis. Proposed mechanisms include metformin-induced mitochondrial complex I inhibition, lactic acidosis…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.